David-Alexandre C. Gros - Feb 1, 2023 Form 4 Insider Report for Eledon Pharmaceuticals, Inc. (ELDN)

Role: Chief Executive Officer, Director
Signature: /s/ David-Alexandre C. Gros
Stock symbol: ELDN
Transactions as of: Feb 1, 2023
Transactions value $: $0
Form type: 4
Date filed: 2/2/2023, 04:56 PM
Previous filing: Feb 2, 2022
Next filing: May 2, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELDN	Stock Option (right to buy)	Award	$0	+300K		$0.00	300K	Feb 1, 2023	Common Stock	300K	$3.08	Direct	F1
transaction	ELDN	Stock Option (right to buy)	Award	$0	+154K		$0.00	154K	Feb 1, 2023	Common Stock	154K	$3.97	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option represents a right to purchase up to 300,000 shares of Common Stock, which options vests with respect to 75,000 shares on February 1, 2024, and then with respect to 6.25% of the underlying shares quarterly over the three year period ending February 1, 2027.
F2	This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on February 1, 2022. The option satisfied the performance criteria with respect to 153,600 shares of underlying Common Stock and these credited shares will satisfy the time-based vesting criteria with respect to 38,400 shares of Common Stock on February 1, 2023, and then with respect to 1/48th of the credited shares monthly over the three-year period ending February 1, 2026.

Content

This option represents a right to purchase up to 300,000 shares of Common Stock, which options vests with respect to 75,000 shares on February 1, 2024, and then with respect to 6.25% of the underlying shares quarterly over the three year period ending February 1, 2027.

This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on February 1, 2022. The option satisfied the performance criteria with respect to 153,600 shares of underlying Common Stock and these credited shares will satisfy the time-based vesting criteria with respect to 38,400 shares of Common Stock on February 1, 2023, and then with respect to 1/48th of the credited shares monthly over the three-year period ending February 1, 2026.